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Purpose:
Cancer patients widely use complementary alternative medicines. Although some remedies have been shown to be of benefi t, there is also a risk of potentially serious interactions with conventional cancer therapies and diagnostic procedures. The aim of this review is to identify the main factors which might make complementary medicines potentially unsafe in cancer.
Method:
Systematic review of potential interactions with chemo-and radiotherapy and review of the purported mechanisms of action.
Results: Four factors were identified. These included the potential modifi cation of the clinical course, interaction with the pharmacodynamics and pharmacokinetics of conventional therapies and potential alterations of investigations. Complementary immunostimulants may be contraindicated in lymphomas and other cancers in which suppression of the immune system is desired. Phytoestrogens could stimulate growth of hormone sensitive cancer cells. Antioxidants should not be used in chemotherapies whose mechanisms of action rely on cell damage through oxidative stress. Many remedies can interact with the cytochrome P450 system thereby potentially changing plasma levels of conventional medicines. However, in vitro effects or fi ndings from animal studies may not translate into clinically relevant effects. Some remedies may interfere with the membrane transporter proteins thereby contributing to multi-drug resistance. Finally some complementary medicines remedies may interfere with unsealed source radiotherapy or nuclear scans.
Conclusions:
Predicting the safety profi le of complementary medicines is complex and may depend on personal and genetic factors. In cancer therapy, where the therapeutic margin of chemotherapies is very narrow, potential risks and benefi ts need to be meticulously evaluated.
Introduction
The use of complementary alternative medicines (CAMs) in patients suffering from cancer is well documented. The reported evidence varies widely and may depend on how CAMs are defi ned. Current estimates suggest that between 7% and 80% of patients may take such treatments. The reasons for using CAMs may be complex. In cancer patients, themes identifi ed evolve around reduction of side effects, reduction of psychological distress, attempts to gain control but also dissatisfaction with conventional care or using CAMs when other treatment options have failed. At the same time, patients may have diffi culties indicating why they chose a specifi c remedy. They may then give more general reasons such as fi ghting cancer, boosting the immune system and enhance well-being.
Increasingly, where CAMs are thought to be benefi cial, the mechanisms of actions are identified. Anti-cancer mechanisms include anti-proliferative, proapoptotic, antioxidant, anti-angiogenic and endocrine properties. Other remedies can interfere with tumour promoter and suppressor genes. Immunological mechanisms include stimulation of B lymphocytes, modifi cation of leukocyte activity, activation of complement factors and cytokines. However, "proof of principle" studies, often conducted in vitro or in animal experiments, need to be followed by systematic clinical testing of effi cacy and safety in human beings. This is a time consuming process, and with the rapid expansion of the availability of information and remedies
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over the Internet patients may be increasingly less willing to wait for scientifically approved results. At the same time they may not be aware of the implications of CAM use for their cancer care. Clinicians need to be aware of CAM-induced side effects or interactions and should be able to identify hazards, advise patients accordingly and avoid uncritical encouragement of potentially harmful use. Ignorance in this area, given the independent usage of CAMs, may lead to criticism and possibly litigation. Equally, patients should be encouraged to disclose information about CAMs to health care professionals.
The aim of this review is to identify the main factors potentially making CAM use unsafe in cancer patients by critically reviewing the evidence base for the mechanism of action of such purported risks.
Methods
The Medline and Cochrane databases were searched for evidence in regard to the safety of CAMs for
In cancer patients, t h e m e s i d e n t i f i e d e v o l v e a r o u n d r e d u c t i o n o f s i d e effects, reduction of psychological distress, attempts to gain control but also dissatisfaction with conventional care or using CAMs when other treatment options have failed.
the treatment of different cancers and potential interactions with chemo-and radiotherapy. Search terms included the identified CAMs categorised as cancer treatments, immunostimulants, antioxidants, CAMs with endocrine and psychotropic properties and other CAMs identifi ed to be used frequently by cancer patients. These terms were combined with various chemotherapeutical ra d i o p h a r m a c e u t i c a l a g e n t s. Additional search terms included "side effects", "adverse drug reaction", "interaction", "antioxidants", "ABC cassette proteins", "P-glycoprotein", "BCRP", "MDRP", "multi-drug resistance", "cytochrome" and "CYP". The recovered papers were reviewed for further relevant references. Webbased resources such as Natural Medicines Comprehensive Database (NMCD) 2006 were also accessed for further information on the identifi ed substances. Where available, reviews summarising safety data and the proposed mechanism of action were used, since presenting all the evidence in detail would have been beyond the scope of this paper, duplicating existing work. For clinical studies, meta-analyses and randomised controlled trials were given priority. However, due to the lack of systematic pharmacovigilance for CAMs, case reports, animal studies and in vitro evidence were also considered.
Results
Four potential factors were identifi ed. These are the potential modifi cation of the clinical course of specifi c tumour types, interaction with the pharmacodynamics and pharmacokinetics of conventional therapies as well as potential alterations of investigations.
Potential modifi cation of clinical course
Potential interactions which could modify the clinical course will vary according to cancer type. Haematological cancers including lymphomas and hormone sensitive cancers may be affected. However, some of the fi ndings are confl icting and pharmacological activity may be dependent on type of extract, dose and length of exposure.
Haematological cancers
In haematological cancers and lymphomas, abnormal and dysfunctional cell lines are produced with detrimental consequences for the immune system. That is why it comes as no surprise that patients may wish to undo damage to the immune system by using CAM immunostimulants. Remedies which may induce leukocyte proliferation and increase cell survival time include echinacea species, mistletoe, cat's claw and astragalus.
Remedies which may i n d u c e l e u k o c y t e p r o l i f e r a t i o n a n d increase cell survival time include echinacea species, mistletoe, cat's claw and astragalus.
In animal and in in vitro e x p e r i m e n t s, e c h i n a c e a h a s been associated with increase o f w h i t e b l o o d c o u n t a n d increase of mononuclear cells and decrease of granulocytes,
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proliferation of T lymphocytes, and proliferation of B lymphocytes and macrophages. However, some studies did not fi nd increase of T cell activity and suggested that echinacea may even have immunosuppressant activity. It is unclear whether these effects are time dependent. Mistletoe has been tested in clinical experiments and shown to lead to increases in total lymphocyte, monocyte and natural killer cell counts. Mistletoe has also been found to be a potent activator of human neutrophil-induced apoptosis. Induction of tumour proliferation such as in B cell lymphoma has been suggested but in vitro evidence has not substantiated this concern. In animal experiments, cat's claw has been shown to increase lymphocyte survival time without increasing proliferation rate. Astragalus stimulates lymphocyte proliferation in healthy individuals. At the same time, astragalus has been shown to improve T cell function. The effects of astragalus may be dose dependent, and immunosupression may occur at a higher dose.
Theoretically, extracts from these plants could boost malignant cell proliferation. Such proliferative effects have to be offset against improved function, for instance through activation of cytokines. However, non-specifi c stimulation of the immune system not targeted at specifi c tumour antigens is unlikely to translate into a specific anticarcinogenic effect.
Hormone sensitive cancers
Sex steroid sensitive cancers include breast, endometrial ovarian, testicular and prostate cancers. Sex steroid deprivation leading to successful therapy of metastatic cancer has long been known and was first reported in 1896. Pharmacological mechanisms of sex steroid deprivation include disruption of the biosynthesis, interference with the hypothalamic-pituitary feedback mechanism targeting luteinising releasing hormone (LRHR), action at end-organ receptors using full or partial antagonists or administration of opposing sex steroids, for instance using oestrogenic agents for the treatment of prostate cancer. Herbal remedies can unfold similar actions, but problems may arise when patients use these remedies to counteract undesired side effects of hormone deprivation. The main concern is that these agents stimulate proliferation of hormone sensitive cancer cells, for instance oestrogenic agents may promote breast cancer growth. These concerns can be diffi cult to prove clinically, since studies which carry a tangible risk of harm, may not be approved by ethics committees. Thus, most research in this area will rely on in vitro and animal experiments.
Oestrogen receptor agonists include panax ginseng, liquorice, red clover, chaste berry and hops. Soy with its active ingredient genistein is an oestrogen receptor agonist by itself but may unfold anti-oestrogenic properties in the presence of oestrogen. Wild yam with its active ingredient diosgenin augments oestrogenic effects. Dong Quai has been also been implicated as a phytoestrogen. Black cohosh exerts its activity on the pituitary axis. Black cohosh binds to oestrogen receptors and depresses the luteinising hormone.
Predicting an effect of these p l a n t s o n b r e a s t c a n c e r c e l l proliferation is not straightforward. For instance, panax ginseng has many different ingredients, some of which are inhibitors of cell growth and proliferation whilst others are inducers of apoptosis and cell cycle arrest. Such properties could outweigh a potentially adverse oestrogenmediated cell proliferative stimulus, but only if such anti-carcinogenic activities were suffi ciently tumour specifi c. Also, oestrogenic activity may depend on the extract chosen. In a recent in vitro study on American ginseng, only a methanol but not a water extract was able to elicit oestrogenic activity and stimulate breast cancer cell proliferation at low concentrations.
Conversely, plants containing γ-linolenic acid such as evening primrose or borage have antioestrogenic properties. These could enhance the therapeutic response to tamoxifen in endocrine sensitive breast cancer through potentiation of the tamoxifeninduced down-regulation of the oestrogen receptor.
Potential interactions with pharmacodynamics of conventional therapies
Cancer chemotherapies exert their function through causation of cell damage, interference with cell metabolism, specifi c immune responses to tumour antigens and reversal of endocrine activity. CAMs are often used to combat the signifi cant adverse effects of such therapies. However, such improvements may come at the expense of a deterioration of the long term prognosis if the chemotherapeutic effect is attenuated.
Antioxidants
Chemically, oxidation is defi ned Predicting an effect of these plants on breast cancer cell proliferation is not straightforward. [ Special Feature ] as the loss of electrons and reduction as a gain of electrons. Loss of electrons can leave the outer shell of an atom unstable producing a free radical. This will try to regain stability by scavenging electrons from another atom, which then becomes unstable. Thus, a chain reaction is started. Free radical production plays a role in many physiological mechanisms at cellular level. Free radicals can lead to cell damage when reactive oxygen species such as superoxide hydrogen peroxides and the hydroxyl radical or reactive nitrogen species such as nitric oxide are involved. For instance, reactive oxygen species can act as secondary messengers in intracellular signaling cascades which induce and maintain the oncogenic phenotype of cancer cells. However, reactive oxygen species can also induce cellular ageing and apoptosis. Although these properties can be used therapeutically they can also cause organ damage as an unwanted effect.
Antioxidants are substances which can donate free radicals w i t h o u t b e c o m i n g u n s t a b l e themselves though electron loss. They come from a variety of sources including metals, minerals and plant products. Commonly used antioxidants include some vitamins and trace elements such vitamins A, C and E, β-carotene, co-enzyme Q10 and selenium. Many plant extracts also have antioxidant properties such as green tea, grape seed, tomato and tumeric. Other antioxidants include N-acetylcysteine, glutathione and melatonin. Zinc, manganese and copper are considered antioxidants when incorporated into superoxide dismutase and iron when incorporated into catalase.
Chemotherapeutic agents r e l y i n g o n o x i d a t i v e s t r e s s include alkylating agents such as cyclophosphamide, anthracycline antibiotics such as doxorubicin, and epipodophyllotoxins such as etoposide. Essentially, these agents produce reactive oxygen species to target DNA thereby arresting cell cycles and inducing apoptosis. Antioxidants may suppress free radical formation and thus compromise the ability of chemotherapeutic agents to destroy micrometastases. This could translate into higher risk of recurrence. Antioxidants may also promote multi-drug resistance mediated through membrane transporter proteins. Expression of p-glycoprotein may be inhibited by reactive oxygen species although the evidence is not consistent. For instance, glutamate has been shown to increase reactive oxygen species formation and enhance expression and activity of p-glycoprotein. This process could be reversed by nacetylcysteine. Equally, radiotherapy depends on irradiation-induced free radical formation and antioxidants may potentially compromise radiotherapy results. However, individual antioxidants vary in action and may not necessarily compromise chemo-and radiotherapy.
Antifolates and folic acid
Probably the best known antifolate is methotrexate (MTX) w h i c h i n t e r f e r e s w i t h D N A biosynthesis. One mechanism of action is based on the inhibition of dihydrofolate reductase leading to accumulation of inactive folate forms. Theoretically, folate supplementation could at least partly reverse the antifolate activity. On the one hand, this could lead to relief of adverse effects including the reduction of treatment related death. On the other hand, this could also adversely affect the effectiveness of chemotherapy. The research evidence remains conflicting. For instance, one study in children with lymphoblastic leukaemia showed that folic acid could stimulate the bone marrow.
Endocrine therapies and immune therapies
The most commonly used sex steroid therapies include antioestrogenic and anti-androgenic therapies ( Table 1) . Mechanisms of action include direct activity at end organ receptors, interference with the hypothalamic-pituitary feedback mechanism or inhibition of synthesis. Anti-androgens currently used include non-steroidal anti-androgens such as flutamide, ketoconazole and fi nasteride. Saw palmetto is an herbal anti-oestrogen commonly used in benign prostate hyperplasia. Anti-oestrogens include tamoxifen, a mixed oestrogen receptor agonist and antagonist and aromatase inhibitors such as anastrozole, which inhibit the production oestrogen through aromatization of adrenal androgens. As well as increasing oestrogen-sensitive cell proliferation, herbal oestrogens could reverse the endocrine action of anti-oestrogenic therapies. However, clinical experience is limited.
Glucocorticoids have cytotoxic as well immunosuppressant effects. They are integrated into many c h e m o t h e ra p e u t i c t r e a t m e n t schemes. CAMs stimulating the immune system, such as astragalus, beta-glucans, cat's claw, echinacea and mistletoe could theoretically modify the immuno-suppressant effects. Some CAMs can also t h e o r e t i c a l l y i n t e r f e r e w i t h monoclonal antibodies by inducing proliferation in the same cell lines targeted by the antibody. This could either lead to synergistic effects as demonstrated at molecular level for beta-glucans or antagonistic effects www.asiabiotech.com 
Pharmacokinetic interactions
The pharmacokinetics of most anti-cancer drugs is highly variable between patients and may be genetically modifi ed. For instance, the oxidative metabolism depends on the cytochrome (CYP) system. Several proteins mediating drug transport through cell membranes have been identifi ed in the context of multi-drug resistance (MDR). Finally direct interactions between CAMs and anti-cancer drugs may possibly lead to accumulation of toxic metabolites. Genetics may account for 20% to 95% of the variability in therapeutic response and toxic effects.
The CYP system
The liver is the most important site of CYP metabolism but other organs can also express these enzymes. About 60% of all clinically used drugs are metabolised through CYP 3A4 including HIV protease inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, warfarin, cyclosporine, ketoconazole, oral contraceptives, some anticonvulsants such as carba-mazepine, digoxine and theophylline. I n a n t i -c a n c e r a g e n t s , metabolisation through the CYP system may not necessarily lead to a decrease in plasma level or diminution of effect. For instance, cyclophosphamide is an inactive pro-drug, which is transformed to the effective substance by CYP2B. Tamoxifen although p h a r m a c o l o g i c a l l y a c t i v e, i s metabolised to much more potent anti-oestrogenic metabolites. C o r t i c o s t e r o i d s a r e m a i n l y metabolised through CYP3A4, but the activity of the metabolites depends on the formulation of the different subtypes. The effects of CYP inducers and inhibitors are essentially differential depending on whether metabolites are more or less active (Table 1) . If metabolites are less active than the original agent, CYP inhibitors increase whereas inducers reduce therapeutic effectiveness. Conversely, if metabolites are more active than the original agent, CYP inhibitors reduce whereas inducers increase therapeutic effectiveness. However, the pharmacodynamic net effects may change in those drugs whose active metabolites undergo CYP mediated inactivation. For instance, cyclophosphamide metabolites are further inactivated by CYP3A4.
This differential metabolic activity has to be considered when the safety profiles of CAMs are evaluated. Many herbal remedies can modify CYP activity, however activity demonstrated in vitro does not always translate into clinical effects (Tables 2a-d) . Also for some remedies, microsomal activity may be extract dependent. Given that the expression of the microsomal enzymes is also affected by age, sex, type of tumour, liver function and genetic polymorphisms as well as type of remedy and extract, the clinical impact on metabolism may Direct interactions between CAMs and a n t i -c a n c e r d r u g s may possibly lead to accumulation of toxic metabolites. Genetics may account for 20% to 95% of the variability in therapeutic response and toxic effects.
In anti-cancer agents, metabolisation through t h e C Y P s y s t e m may not necessarily lead to a decrease in plasma level or diminution of effect.
be extremely diffi cult to predict.
ABC transporters
The ABC cassette genes represent proteins which bind to ATP and use this energy to drive various molecules through cell membranes. The transport is mostly unidirectional. This can lead to drug resistance in cancer chemotherapy when drugs are increasingly transported out of the target cells. Multi-drug resistance can occur when a transporter protein is stimulated by one agent but the resulting resistance affects several agents transported by the respective protein. Three ABC genes seem to be responsible for nearly all the drug resistance in cancer chemotherapy: ABCB1 encoding p-glycoprotein (p-GP), ABCC1 encoding multi-drug sistance associated protein 1 (MRP1) and ABCG2 encoding breast cancer resistance associated protein (BCRP). However, not all chemotherapies are affected by these transporter proteins (Table 1) . Equally, although many CAMs may also exert such an effect (Tables 2a-d) , the clinical relevance of such pharmacokinetic interactions remains unclear.
Toxic effects
Toxic effects are a great concern not only in cancer chemotherapy but also in CAMs. Such concern may be even greater in view of compromised
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liver and kidney function found in many cancer patients. Here three examples are given which have raised clinical concerns and highlight general principles.
Vitamin C and methotrexate
Many cancer patients take supplements and over 10% may take doses higher than recommended. However, the combination of high dose vitamin C and methotrexate (MTX) should be avoided since this could lead to kidney damage and increased MTX plasma levels and thus MTX toxicity. Vitamin C acidifi es urine. This leads to the precipitation of MTX and its less water soluble metabolites 7-hydroxy-MTX and 4-diamino-N(10)-methylpteroic acid (DAMPA), which cannot be excreted.
Kava: alcohol or water extracts?
Kava has been withdrawn from the market in many high-income countries due to concerns about liver toxicity. About 78 cases have been reported. Of these, 11 patients required a liver transplant, and four died. Reduction of liver glutathione, an antioxidant which plays a role in hepatic detoxifi cation, has been implicated as mechanism of this adverse reaction. The glutathione content in a kava extract depends on the mechanism of extraction. Whereas in aqueous extracts the glutathione is extracted along with the kavalactones, in acetone or alcohol solutions glutathione is not extracted. This would explain why the indigenous Polynesian population using water mixture have not developed signifi cant liver problems, whilst medicinal use mostly relying on acetone or alcoholic extracts has led to reports of liver toxicity. Inhibition of CYP3A4, CYP1A2, CYP2C9, and CYP2C19 may also be more pronounced for the commercial rather that the traditional preparations. However, this hypothesis still requires confi rmation.
Pyrrolizidine alkaloids and hepatotoxicity
Many plants of the boraginaca and senecio species contain genotoxic pyrrolizidine alkaloids (NMCD: Borage). The major metabolites of many of these compounds are (+/−) 6,7-dihydro-7-hydroxy-1-(hydroxymethyl)-5H-pyrrolizine (DHP) and pyrrolizidine alkaloid N-oxides. DHP can react with DNA to form a set of eight DNA adducts involved in the formation of liver tumours. Additionally, under hypoxic conditions N-oxides can be converted to DHP and the parent alkaloid, whereas under oxidative conditions this reaction is inhibited. CYP 3A4 inhibitors also hinder this reaction but conversely CYP3A4 inducers may facilitate DHP production.
Potential interaction with nuclear medicine
Most cancer physicians will be aware of radiopharmaceutical interactions with conventional medicines. For instance the uptake of 131I and 123I MIBG (meta-iodobenzyl-guanidine) are affected by thyroxin and tricyclic anti-depressants or decongestants, respectively. CAMs can equally compete for uptake targeting the same mechanisms as conventional medicines. This may affect unsealed source radiotherapy such as treatment for thyroid cancer, phaeochromocytoma, some gastro- Biography entero-pancreatic-neuro-endocrine tumours, as well as neural crest, small cell lung cancer and some lymphomas (Table 3a) . Diagnostic procedures such as glomerular fi ltration rate (GFR) measurements, bone scans, cholescintigraphy, adenosine perfusion studies and MDR scans may be equally affected (Table 3b) . Unfortunately at present, the clinical evidence for such potential interactions is extremely limited and prediction depends on the hypotheses of the mechanism of action. In clinical practice, such interactions may go unnoticed and may possibly account for a proportion of unexplained or unexpected results of nuclear scans.
